Quote
82.29
+2.36 (+2.95%)
We have scored 50 news catalysts on DXCM (DXCM) over the past 12 months. Coverage across the window leans mixed (average ticker sentiment −0.08). Most of the impact sits in institutional appeal and sector healthcare.
Market cap
—
P/E
—
EPS
—
Beta
—
52W range
—
Day range
79.78–85.25
Open
81.52
Prev close
79.93
Volume
8.6M
Avg volume
—
Dividend
—
IPO
—
No scored news tagged DXCM or its network in the window yet.
Show more DXCM articles →Analysts publish price targets on DXCM, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
18 analyst price targets from $85 to $105
as of 2026-09-23
The market is within 3% of the median target — broadly agreeing with the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about DXCM — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of DXCM, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for DXCM: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The price sits at the 22nd percentile of the published model spread, within 3% of the median target, meaning it broadly agrees with the endorsed consensus and explicitly declines to pay for the 17% upside offered by the lone bull case.
What the disagreement turns on
Whether the Type 2 non-insulin and prediabetic markets will actually deliver the volume surge the bull case requires; unit_volumes can measure this, but consumer_attention for the over-the-counter Stelo product cannot be tested with the data wired.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $89.53 on 2026-09-23 — the quote has since moved -8%, so read this as a record of what was priced in then, not now.
